Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

NCT04572451 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Unresectable Solid Tumors
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Nivolumab

Interventions

DRUG: nivolumab
DRUG: BMS-986253
RADIATION: Stereotactic Body Radiotherapy (SBRT)

Sponsor

Yana Najjar

Collaborators

[object Object]